Detalles de la búsqueda
1.
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
N Engl J Med;
389(14): 1298-1309, 2023 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792613
2.
The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study.
BMC Psychiatry;
19(1): 247, 2019 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31391065
3.
Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study.
BMC Psychiatry;
18(1): 80, 2018 03 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29587672
4.
Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study.
Front Psychiatry;
14: 1250987, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38025416
5.
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry.
Front Psychiatry;
14: 1250980, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38025433
6.
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.
Neuropsychiatr Dis Treat;
18: 1127-1132, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35707064
7.
The burden of suicidal ideation across Europe: a cross-sectional survey in five countries.
Neuropsychiatr Dis Treat;
15: 2257-2271, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31496708
8.
Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder.
Neuropsychiatr Dis Treat;
14: 2861-2877, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30464471
9.
Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study.
Neuropsychiatr Dis Treat;
14: 1339-1350, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29872301
10.
Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
Neuropsychiatr Dis Treat;
14: 239-249, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29386897
11.
The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.
Brain Behav;
7(3): e00622, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28293465
12.
Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study.
Neuropsychiatr Dis Treat;
13: 2151-2165, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28860772
13.
Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
Eur J Health Econ;
7(2): 137-44, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16670912
14.
The effect of vortioxetine on health-related quality of life in patients with major depressive disorder.
Clin Ther;
37(10): 2309-2323.e6, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26346592
15.
16.
Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland.
Clin Drug Investig;
24(7): 373-84, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-17516724
17.
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Curr Med Res Opin;
30(12): 2589-606, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25249164
18.
The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
Eur J Health Econ;
15(8): 791-800, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23928827
19.
Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease.
CNS Drugs;
27(7): 573-82, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23765561
20.
Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands.
Neuropsychiatr Dis Treat;
7: 313-7, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21822384